6.
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik W, Tosti A
. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295(5562):2097-100.
DOI: 10.1126/science.1068440.
View
7.
Yanada M, Yamamoto K, Emi N, Naoe T, Suzuki R, Taji H
. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003; 32(8):801-7.
DOI: 10.1038/sj.bmt.1704232.
View
8.
Zuo W, Yu X, Liu X, Chang Y, Wang Y, Zhang X
. The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation. Front Immunol. 2022; 13:814334.
PMC: 9101514.
DOI: 10.3389/fimmu.2022.814334.
View
9.
Green M, Leisenring W, Xie H, Walter R, Mielcarek M, Sandmaier B
. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood. 2013; 122(7):1316-24.
PMC: 3744995.
DOI: 10.1182/blood-2013-02-487074.
View
10.
Bjorkstrom N, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson M
. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood. 2010; 116(19):3853-64.
DOI: 10.1182/blood-2010-04-281675.
View
11.
Yoon J, Lee S, Kim H, Jeon Y, Lee S, Cho B
. Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission. Oncotarget. 2016; 7(13):17230-41.
PMC: 4941383.
DOI: 10.18632/oncotarget.7347.
View
12.
Elmaagacli A
. CMV and relapse: what has conditioning to do with it?. Biol Blood Marrow Transplant. 2013; 20(1):1-2.
DOI: 10.1016/j.bbmt.2013.11.004.
View
13.
Koldehoff M, Ross S, Duhrsen U, Beelen D, Elmaagacli A
. Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma. Leuk Lymphoma. 2016; 58(4):822-833.
DOI: 10.1080/10428194.2016.1217524.
View
14.
Goldsmith S, Slade M, Dipersio J, Westervelt P, Lawrence S, Uy G
. Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Haematologica. 2016; 101(11):e465-e468.
PMC: 5394884.
DOI: 10.3324/haematol.2016.149880.
View
15.
Jang J, Hwang D, Chung H, Kim S, Eom J, Jeung H
. Early Cytomegalovirus Reactivation and Expansion of CD56CD16DNAM1 Natural Killer Cells Are Associated with Antileukemia Effect after Haploidentical Stem Cell Transplantation in Acute Leukemia. Biol Blood Marrow Transplant. 2019; 25(10):2070-2078.
DOI: 10.1016/j.bbmt.2019.06.008.
View
16.
Teira P, Battiwalla M, Ramanathan M, Barrett A, Ahn K, Chen M
. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016; 127(20):2427-38.
PMC: 4874224.
DOI: 10.1182/blood-2015-11-679639.
View
17.
Mariotti J, Maura F, Spina F, Roncari L, Dodero A, Farina L
. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014; 20(6):885-90.
DOI: 10.1016/j.bbmt.2014.02.015.
View
18.
Jeljeli M, Khourouj V, Porcher R, Fahd M, Leveille S, Yakouben K
. Relationship between cytomegalovirus (CMV) reactivation, CMV-driven immunity, overall immune recovery and graft-versus-leukaemia effect in children. Br J Haematol. 2014; 166(2):229-39.
DOI: 10.1111/bjh.12875.
View
19.
Peled J, Jenq R
. Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant. Leuk Lymphoma. 2016; 58(4):759-761.
PMC: 5354121.
DOI: 10.1080/10428194.2016.1239265.
View
20.
Porter D, Alyea E, Antin J, DeLima M, Estey E, Falkenburg J
. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010; 16(11):1467-503.
PMC: 2955517.
DOI: 10.1016/j.bbmt.2010.08.001.
View